Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, Phase II study. Efficacy is not a primary endpoint in this study;
however, progression-free survival will be followed and determined for the patients in this
study. Approximately 50 patients are planned to be enrolled in this study.